Considering the dramatic impact of its E4 allelic variant on Alzheimer’s disease risk, apolipoprotein E arguably has drawn scant attention from AD drug developers, but recent research may help turn the tide. At a workshop organized by Yadong Huang of the Gladstone Institute of Neurological Disease in San Francisco, and held 30 January to 1 February, several researchers presented on this topic. Kelly Bales of Pfizer Global Research and Development, Groton, Connecticut, told attendees about the company’s efforts to tweak brain levels in AD mice with small molecules. Nga Bien-Ly, a postdoc in Huang’s lab, reported finding less Aβ buildup in AD mice with halved levels—whether the reduction was present since birth or induced during adulthood. And in a widely noted Science paper published online on February 9, researchers report that AD mouse models clear amyloid-β and regain cognitive function within hours when given an approved cancer drug that enhances endogenous transcription (see ARF related news story on Cramer et al., 2012). The overall picture presents a riddle. Pharmacological data suggest that raising compounds benefits AD mice, while genetic studies indicate that less is better. Even so, scientists are getting a better handle on ApoE’s physiological role in the brain, and potential therapeutic strategies for changing brain ApoE levels are emerging.

Based on the promising mouse data reported in Science, the cancer drug bexarotene is headed for a Phase 1b biomarker trial in healthy adults. Bexarotene promotes ApoE transcription by activating retinoid X receptor (RXR)—a protein that hooks up with peroxisome proliferator-activated receptor γ (PPARγ) or liver X receptors (LXRs) to form heterodimeric transcription factors.

At the Gladstone workshop, Bales described her team’s characterization of a histone deacetylase (HDAC) inhibitor that was among the top hits from a screen for small molecules that boost brain ApoE. By blocking the enzymes that compress DNA into a less accessible state, the compound (MS275) stimulates transcription of ApoE, causing three- to fourfold increased protein levels at an effective concentration of ~200 nM, Bales said. When they gave the compound orally to knock-in mice expressing human ApoE3 at the endogenous mouse locus, the researchers saw higher ApoE levels in plasma and hippocampus, and a trend for increased ApoE in CSF, Bales reported. Preclinical development with ApoE-raising compounds is ongoing, Bales said.

Meanwhile, new work out of the Huang lab adds to a emerging body of evidence suggesting that AD mice do better with less ApoE, not more. In a recent report by David Holtzman and colleagues at Washington University, St. Louis, Missouri, APP/PS1(L166P) mice with just one copy of human ApoE (either E3 or E4) had less amyloid pathology than AD mice with both copies of the human gene (ARF related news story on Kim et al., 2011). In San Francisco, Bien-Ly reported similar results in J20 mice, a different APP-overexpressing AD model. The work has been submitted for publication.

Bien-Ly and colleagues crossed J20 animals with human ApoE3 or ApoE4 knock-in mice, and measured Aβ burden in ApoE hemizygous and homozygous offspring at six or 12 months of age. At six months, having less ApoE hardly seemed to matter—hemizygotes and homozygotes had comparable levels of soluble and insoluble brain Aβ, suggesting that a single copy of ApoE does fine for Aβ clearance, Bien-Ly said. That was not the case for older AD mice. At 12 months of age, ApoE4 homozygotes accumulated more amyloid than J20 mice with a single copy of ApoE4, and the homozygotes had more brain Aβ42 and more plaques than did J20/ApoE3 animals. “In aged mice, you see not only isoform-specific effects, but also a gene-dose effect [on Aβ buildup],” Bien-Ly reported.

Bien-Ly and colleagues took things a step further by tweaking the knock-in strains to have loxP sites flanking the human ApoE transgene. This allowed the researchers to dial down ApoE levels during adulthood using Cre recombinase. When they injected Cre-expressing adenoviruses into the hippocampus of six-month-old ApoE4-expressing J20 mice, ApoE levels fell 10 to 15 percent, and a month after injection, insoluble Aβ42 levels had plunged by half. These data suggest that decreasing brain ApoE4, or even ApoE3, could be a potential therapeutic strategy for AD, Bien-Ly said. Thus far no behavioral assessments have been reported for J20 or APP/PS1(L166P) ApoE hemizygotes.

There remains an apparent discrepancy between genetic manipulation of ApoE, which suggests that more ApoE is bad, and pharmacological agents that enhance Aβ clearance and improve cognition while increasing brain ApoE. With regard to Aβ burden, the genetic data argue that “you would probably want to lower ApoE, especially E4, not increase it,” noted Joachim Herz of the University of Texas Southwestern, Dallas, in an e-mail to ARF. Huang agreed. “No matter whether you think about Aβ-related or Aβ-independent effects, increasing ApoE4 is bad,” he said. When neurons turn on ApoE4, they generate toxic E4 fragments that can lead to tau pathology, mitochondrial impairment, and eventually cognitive loss and neurodegeneration (Huang, 2010), he said. And now, these recent data suggest there may be bad consequences, e.g., more Aβ deposition, even with ApoE3.

There is another way to consider the confusion between genetic and pharmacologic data. In the brain, ApoE “only functions in the context of high-density lipoproteins (HDLs),” said Gary Landreth, Case Western Reserve University, Cleveland, Ohio. Landreth was the principal author on the recent Science paper linking an ApoE boost to improved pathology and cognition. “More ApoE is not necessarily a good thing unless it is lipidated,” he told Alzforum. Transport proteins such as ATP-binding cassette transporter (ABCA1) load membrane lipids and ApoE onto HDL particles, which promote Aβ degradation (see ARF related news story on Jiang et al., 2008). Bexarotene and other LXR/RXR agonists not only turn on ApoE expression, but also upregulate ABCA1 and other proteins that help assemble HDL particles. “Simply overproducing ApoE without inducing the machinery to make HDLs appears not to be a great thing,” Landreth said, based on recent genetic data showing ApoE dosage effects.

Ascribing harm or benefit to ApoE modulation is challenging also because not all effects are isoform-specific. For example, complete lack of ApoE impairs Aβ clearance by astroglia in culture (see Terwel et al., 2011), arguing against decreasing ApoE as a therapeutic strategy. However, the E4 isoform worsens long-term potentiation and Aβ-induced neurotoxicity (see Trommer et al., 2005; Trommer et al., 2004; Manelli et al., 2007). “The implications of ApoE4 having some additional gain-of-toxic-function effects may need to be addressed before we can get therapeutics to work,” commented Greg Cole of the University of California, Los Angeles. Mary Jo LaDu and Leon Tai of the University of Illinois, Chicago, expressed similar concerns in an e-mail to ARF (see full comment).

And yet, amid the debate about whether to modulate brain ApoE levels up and down, some think the real issue lies elsewhere. “I do not view either the raising or lowering of ApoE levels as a viable therapeutic approach,” wrote Allen Roses of Duke University in Durham, North Carolina, in an e-mail to ARF. In his view, therapeutic compounds should target interactions between ApoE fragments and intraneuronal mitochondria, since these associations set off a cascade of mitochondrial problems that contribute to neuronal death (see Chang et al., 2005; Roses et al., 2007).

“It boils down to the question of whether Aβ clearance and plaque formation are primary determining factors for ApoE4-mediated neurodegeneration, or whether a combination of other factors, including neuroprotective effects of LXR/RXR agonists and HDAC inhibitors, will dominate,” Herz wrote.—Esther Landhuis.

This is Part 1 of a two-part story. See Part 2.

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

No Available Comments

Comments on Primary Papers for this Article

No Available Comments on Primary Papers for this Article

References

News Citations

  1. Upping Brain ApoE, Drug Treats Alzheimer's Mice
  2. Lowering ApoE Brings Down Amyloid in Mice
  3. ApoE’s Secret Revealed? Protein Promotes Aβ Degradation
  4. San Francisco: GABA Neurons Blamed for Memory Loss in ApoE Mice

Paper Citations

  1. . ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science. 2012 Mar 23;335(6075):1503-6. PubMed.
  2. . Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J Neurosci. 2011 Dec 7;31(49):18007-12. PubMed.
  3. . Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. Trends Mol Med. 2010 Jun;16(6):287-94. PubMed.
  4. . ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008 Jun 12;58(5):681-93. PubMed.
  5. . Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. J Neurosci. 2011 May 11;31(19):7049-59. PubMed.
  6. . ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. Neurobiol Dis. 2005 Feb;18(1):75-82. PubMed.
  7. . ApoE isoform affects LTP in human targeted replacement mice. Neuroreport. 2004 Dec 3;15(17):2655-8. PubMed.
  8. . Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol Aging. 2007 Aug;28(8):1139-47. PubMed.
  9. . Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18694-9. PubMed.
  10. . Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J. 2007 Feb;7(1):10-28. PubMed.

Other Citations

  1. APP/PS1(L166P) mice

External Citations

  1. workshop
  2. bexarotene

Further Reading

Papers

  1. . ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science. 2012 Mar 23;335(6075):1503-6. PubMed.

News

  1. Australia Report: Aβ Toxicity, ApoE
  2. Lowering ApoE Brings Down Amyloid in Mice
  3. Chicago: 2nd Annual Symposium Explores ApoE
  4. St. Louis: ApoE Receptors—Hold Sway Over Synaptic Function
  5. Upping Brain ApoE, Drug Treats Alzheimer's Mice
  6. ApoE’s Secret Revealed? Protein Promotes Aβ Degradation